No Data
Minsheng Securities: Triple resonance moving upwards, focusing on pharmaceutical innovation and Consumer in 2025.
Looking ahead to 2025, there is a bullish outlook on the upward resonance of policy, fundamentals, and market sentiment, comprehensively optimistic about the pharmaceutical sector, with a focus on high-quality assets in pharmaceutical innovation and consumer sectors.
Hong Kong stocks are moving | CRO Concept stocks rose broadly in the morning, with most companies' overseas Business improving on a quarter-on-quarter basis. Institutions are Bullish on the Industry entering a stable growth phase.
CRO Concept stocks generally rose in the morning. As of the time of writing, Asymchem Laboratories (06821) rose by 4.16%, trading at 52.6 Hong Kong dollars; WUXI APPTEC (02359) rose by 3.53%, trading at 55.8 Hong Kong dollars; PHARMARON (03759) rose by 3.06%, trading at 14.14 Hong Kong dollars.
Highly resilient! Leading CRO companies have stabilized their fundamentals, but the shadow of the biosafety bill may still linger next year | Year-end review.
① In 2024, the USA Biodefense Act will disrupt CROs throughout the year and may continue next year; ② In the first three quarters of this year, over half of listed companies experienced revenue growth, and leading CROs demonstrated resilience; ③ Research on popular targets such as ADC, GLP-1, and bispecific antibodies will continue to be hot; ④ In 2025, the performance of leading CROs and small to medium enterprises may further diverge.
Aadi Bioscience Rockets 72% on Key Updates
WuXi Biologics Included in UNGC 20 Case Examples of Sustainable Development for 20 Years Collection
Leading Green CRDMO Driven by Innovation for a Healthier Future Offering End-to-end Green Biologics Solutions for the Entire Industry SHANGHAI, Dec. 12, 2024 /PRNewswire/ -- WuXi Biologics ("WuXi Bio"
[Brokerage Focus] CEB International raises WUXI BIO (02269) Target Price by 68.5%. Global Biomedical financing recovery is Bullish on its valuation and performance recovery.
Jingwu Financial News | According to the Research Reports from CCB International, it is expected that the biosafety bill will most likely fail in legislation, which is Bullish for WUXI BIO (02269) to continue achieving performance growth in a relatively stable Operation environment. With the recovery of Global Biomedical financing, the bank is Bullish on the Company Valuation and performance recovery. The bank maintains a Buy rating for WUXI BIO and raises the Target Price based on DCF valuation to HKD 22.88 (previous value: HKD 13.58). The bank expects WUXI BIO's 2024E/25E/26E revenue to grow year-on-year by 7.1%/12.4%/13.9%, with adjusted Net income growing year-on-year by 0.8%/1.
